Soligenix announced that its Phase 3 FLASH 2 trial for HyBryte, a treatment for cutaneous T-cell lymphoma (CTCL), was stopped early after an interim analysis showed the study was unlikely to meet its efficacy goals. This outcome is disappointing as the first Phase 3 trial showed significant lesion reduction, but the second trial did not replicate these results over 18 weeks. The company will analyze the data further to identify any patient subsets that might benefit and consider next steps including discussions with regulators and exploring other pipeline assets like dusquetide for Behçet's Disease. With $5.9 million in cash, Soligenix is also open to strategic options such as mergers or acquisitions.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
Wendy's is running a $1 promotion on small Classic Chocolate or Vanilla Frosty from July 20 to August 23, with early access for Wendy's Rewards members on July 19 in celebration of National Ice Cream Day. The offer is redeemable via the Wendy's app a...
Inseego Corp. will release its financial results for the second quarter of 2026 on August 5, after market close. The company will hold a conference call the same day to discuss the results and business outlook. Investors can access the earnings repor...
Dyadic International has expanded its bio-industrial pipeline with a new proprietary enzyme program focused on advanced cellulose processing, building on the success of its EN3ZYME™ product. This initiative leverages Dyadic's Dapibus™ platform to str...
